Engineering and Development

Legal and Compliance

Accounting and Finance

Management and Executive

Customer Service and Support

Chief Human Resources Officer

President

Revolution Medicines pancreatic cancer treatment granted orphan status

FDA names 9 first recipients of 1- to 2-month priority review vouchers

Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2025

Revolution Medicines Awarded Voucher for Daraxonrasib (RMC-6236) Under FDA Commissioner's National Priority Voucher Pilot Program

Senior Director, Clinical Pharmacology

Revolution Medicines is a clinical-stage precision oncology company focused on developing novel targeted therapies for RAS-addicted cancers. The role involves leading clinical pharmacology efforts, collaborating with product teams, and authoring key regulatory documents for clinical development milestones.

VP, Talent Acquisition

Executive Director, Head of Talent Acquisition

Medical Director

Director, Cancer Pharmacology

Sign up with Google

Sign in with Google